CClinicalTrials.gg
CompletedNCT04801394Updated Jun 15, 2022

Retrospective Analysis on Large Incisional Hernia in High Risk Patients

An interventional study of hernioplastic and insertion of FLaPp® composite mesh in Incisional Hernia and Large Incisional Hernia, sponsored by University of Campania Luigi Vanvitelli. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-15.

Sponsored by University of Campania Luigi Vanvitelli · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 years 11 months after the study started (first participant enrolled Apr 2010, registered Mar 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Large incisional hernia (LIH) is a challenging condition where the abdominal wall is hopelessly compromised. Nowadays the best treatment option in this particularly frail subset of patients is a major issue. The Auhtors proposed the clinical experience with an innovative approach with the composite Free Lateral Polypropylene prosthesis (FLaPp®) mesh fashioned as "neoperitoneum" analyzing its feasibility and short/medium term results.

02

Conditions studied

  • Incisional Hernia
  • Large Incisional Hernia
03

In context

Hernia

1,096 studies on the registry are indexed under Hernia; 132 are open to participants now.

This study's enrollment of 43 is below the median of 80 across 739 interventional studies indexed under Hernia.

Browse Hernia studies →

Lead sponsor

University of Campania Luigi Vanvitelli is the lead sponsor of 170 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • symptomatic patients with midline Large incisional hernia

Exclusion criteria

Exclusion Criteria:

  • lateral incisional hernias
  • collagen diseases
  • patients who recently have undergone chemotherapy and/or radiation therapy
  • patients with acquired immunodeficiency
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Mesh Group

    Patient with large incisional hernia treated with FLaPp® mesh as neoperineium

    Procedure: hernioplastic and insertion of FLaPp® composite mesh

Interventions

  • Procedurehernioplastic and insertion of FLaPp® composite mesh

    After the reduction of the large incisional hernia, the polypropylene transparent film of this mesh (lower flap) was sutured to the margins of the residual peritoneum and posterior rectus sheath as a "neo-peritoneum"; the macroporous light polypropylene layer (upper flap) was then sutured circumferentially with full-thickness transabdominal stitches in the retromuscular space.

06

What researchers measure

Primary outcomes

  1. Early surgical outcome of FLaPp® prosthesis classified according to Clavien Dindo Classification

    evaluation of feasibility of FLaPp® prosthesis in patients affected by LIH by the assessment of postoperative morbidity classified according to Clavien Dindo Classification

    Time frame: one month

  2. Evaluation of pain after FLaPp® prosthesis

    Evaluation of postoperative pain through Visual Analague Scale

    Time frame: one month

  3. Mortality after FLaPp® prosthesis

    Rate of posoperative mortality after FLaPp® prosthesis

    Time frame: One month

Secondary outcomes

  1. incisional hernia recurrence at medium term

    assessment of postoperative recurrence after 36 months evaluated with clinical outcpatient control and CT scan

    Time frame: 36 months

  2. Patients' satisfatcion after FLaPp® prosthesis

    Evaluated through the so-called 36 items Short-Form health survey

    Time frame: 36 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04801394
Lead sponsor
University of Campania Luigi Vanvitelli
Responsible party
Claudio Gambardella (Clinical Professor, University of Campania Luigi Vanvitelli) — Principal investigator
First posted
Mar 17, 2021
Start date
Apr 1, 2010
Primary completion
Dec 31, 2016
Completion
Dec 31, 2016
Last update
Jun 15, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion